BioScience Laboratories, Inc. and Synomics Pharmaceutical Services Announce Their Partnership to Provide Phase 1 Clinical Study Services
BioScience Laboratories, Inc. and Synomics Pharmaceutical Services announced today their formal partnership to provide a fully integrated phase 1 clinical study capability for trials in healthy human subjects.

BOZEMAN, MT, October 10, 2009 /24-7PressRelease/ -- BioScience Laboratories, Inc. and Synomics Pharmaceutical Services announced today their formal partnership to provide a fully integrated phase 1 clinical study capability for trials in healthy human subjects to provide drug manufacturers with a single source for outsourcing clinical trials.

The combination of BioScience Laboratories' 18 years of experience conducting clinical trials and Synomics Pharmaceutical Services' strong reputation for providing pre-clinical and clinical bioanalysis and analytical chemistry services provides drug manufacturers with an outsourcing solution to conduct all aspects of phase 1 clinical trials in a GCP and GLP compliant environment.

In recent years, drug manufacturers have experienced an increased demand on the quality of data from clinical trials. Combined with the drive to decrease the drug development timeline, the industry trend is back towards using contract research organizations located in the United States. To assure FDA acceptance drug manufacturers are requiring, more than ever, clinical trials that are conducted strictly in compliance with the FDA, GCP and GLP guidelines.

For drug manufacturers wanting to realize the revenue of bringing a product to market, it is critical to select a contract research organization that conducts the clinical trial on time, on budget, and with resulting data that is suitable for FDA submission. The partnership between BioScience Laboratories and Synomics Pharmaceutical Services allows a single point of project management with the full array of bioanalytical and clinical trials capabilities.

"Our eighteen years experience in conducting clinical trials combined with Synomics Pharma's reputation for a strong quality system and state-of-the art bioanalytical capabilities is a winning combination as a single source for outsourcing phase 1 clinical trials." - Daryl Paulson, Ph.D., CEO of BioScience Laboratories

"Synomics Pharma's comprehensive quality management system reduces regulatory risk," said John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. "Our active involvement with the Bioanalytical Quality Standards Initiative (BQSI) for the implementation of ICH Q10 for clinical trials demonstrates our commitment to consistency and quality in clinical bioanalysis. The alliance between Synomics Pharma and BioScience Laboratories produces a versatile topical clinical phase I trial service offering that will be highly beneficial to the industry."

Press Release Contact Information:

Jim Verzuh
BioScience Laboratories
Marketing
300 N Willson
Bozeman, Montana
USA 59715
Voice: 406-587-5735
Website: Visit Our Website